NEUROCRINE BIOSCIENCES INC NBIX

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders.

Our portfolio of products includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc. In addition, we have a diversified portfolio of multiple compounds in mid- to late-phase development across our core therapeutic areas and an expanding early-phase pipeline that includes a range of modalities including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies.

Last close 142.70 2026-10-23
Market cap $14.51B 2026-06-30 share count
52-week range 122.14 - 186.12

Valuation FY2025 figures against the last close

P/S5.1x
P/E30.6x
P/FCF19.4x
EV/EBITDA22.5x
Dividend yield—
Diluted EPS4.67

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788.1M$451.2M$161.6M$15.0M
Cost of revenue $52.1M$34.0M$39.7M$23.2M$14.3M$10.1M—$4.9M$1.3M$0
Gross profit $2.81B$2.32B$1.85B$1.47B$1.12B$1.04B—$446.3M$160.4M$15.0M
R&D ———————$160.5M$121.8M$94.3M
SG&A $1.16B$1.01B$887.6M$752.7M$583.3M$433.3M$354.1M$248.9M$169.9M$68.1M
Total operating expenses $2.24B$1.78B$1.64B$1.24B$1.03B$882.9M$715.8M$414.4M$293.0M$162.4M
Operating income $619.1M$570.5M$250.9M$249.0M$102.5M$163.0M$72.3M$36.8M-$131.4M-$147.4M
Interest expense ——$4.6M$7.1M$25.8M$32.8M$32.0M$30.5M$19.5M$0
Pre-tax income $705.4M$486.0M$332.1M$213.9M$101.4M$106.7M$46.5M$21.8M-$142.5M-$141.1M
Income tax $226.8M$144.7M$82.4M$59.4M$11.8M$300.6M$9.5M$700.0K$0$0
Net income $478.6M$341.3M$249.7M$154.5M$89.6M$407.3M$37.0M$21.1M-$142.5M-$141.1M
EPS, basic 4.813.402.561.610.954.380.400.23-1.62-1.63
EPS, diluted 4.673.292.471.560.924.160.390.22-1.62-1.63
Shares, diluted (wtd. avg.) 102.5M103.7M101.0M98.9M97.9M97.8M95.7M95.4M88.1M86.7M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $713.0M$233.0M$259.1M$270.7M$344.0M$190.3M$115.5M$147.2M$259.2M$88.2M
Short-term investments $767.4M$843.1M$780.5M$726.4M$370.5M$613.9M$558.2M$509.2M$261.2M—
Receivables $686.8M$479.1M$439.3M$350.0M$185.5M$157.1M$126.6M$57.4M$31.1M$0
Inventory $69.0M$57.4M$38.3M$35.1M$30.5M$28.0M$17.3M$10.9M$1.0M—
Total current assets $2.52B$1.72B$1.61B$1.45B$972.8M$1.02B$831.0M$737.8M$554.9M$310.4M
Property, plant and equipment $89.8M$82.6M$70.8M$58.6M$58.6M$44.6M$41.9M$33.9M$10.8M$6.3M
Goodwill —$5.7M$5.8M$5.4M$0—————
Other intangibles —$36.5M$35.5M$37.2M$0—————
Total assets $4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993.2M$817.6M$365.1M
Accounts payable $674.3M$461.6M$448.8M$347.6M$225.8M$168.7M$141.3M$86.4M$5.6M$5.1M
Total current liabilities $743.4M$507.7M$654.8M$537.7M$245.8M$186.5M$565.3M$88.2M$54.4M$30.4M
Total liabilities $1.38B$1.13B$1.02B$660.9M$698.5M$608.5M$669.1M$512.4M$445.5M$50.2M
Retained earnings $447.7M$29.2M-$157.1M-$406.8M-$635.8M-$725.4M-$1.13B-$1.18B-$1.20B-$1.06B
Total equity $3.25B$2.59B$2.23B$1.71B$1.37B$1.13B$636.9M$480.8M$372.2M$314.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $782.7M$595.4M$389.9M$339.4M$256.5M$228.5M$147.0M$101.4M-$94.3M-$106.2M
Depreciation and amortisation $26.0M$23.5M$17.8M$15.1M$10.9M$8.6M$7.4M$4.0M$2.4M$1.5M
Stock-based compensation $217.9M$195.5M$194.3M$173.1M$134.2M$100.0M$75.3M$58.1M$42.5M$28.5M
Capital expenditure $34.0M$38.2M$28.3M$16.5M$23.4M$10.9M$14.7M$24.8M$6.9M$4.1M
Investing cash flow -$264.4M-$126.8M-$467.1M-$177.1M-$130.2M$4.1M-$211.1M-$242.9M-$251.3M$113.0M
Financing cash flow -$38.3M-$486.7M$65.3M-$234.3M$27.4M-$157.8M$32.4M$29.5M$516.6M$2.4M
Buybacks $167.7M$300.0M$0$0——————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000914475-26-000015.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B 3B Revenue, FY2016: 15M Gross profit, FY2016: 15M Net income, FY2016: -141.1M Revenue, FY2017: 161.6M Gross profit, FY2017: 160.4M Net income, FY2017: -142.5M Revenue, FY2018: 451.2M Gross profit, FY2018: 446.3M Net income, FY2018: 21.1M Revenue, FY2019: 788.1M Net income, FY2019: 37M Revenue, FY2020: 1B Gross profit, FY2020: 1B Net income, FY2020: 407.3M Revenue, FY2021: 1.1B Gross profit, FY2021: 1.1B Net income, FY2021: 89.6M Revenue, FY2022: 1.5B Gross profit, FY2022: 1.5B Net income, FY2022: 154.5M Revenue, FY2023: 1.9B Gross profit, FY2023: 1.8B Net income, FY2023: 249.7M Revenue, FY2024: 2.4B Gross profit, FY2024: 2.3B Net income, FY2024: 341.3M Revenue, FY2025: 2.9B Gross profit, FY2025: 2.8B Net income, FY2025: 478.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $15.0M $161.6M $451.2M $788.1M $1.05B $1.13B $1.49B $1.89B $2.36B $2.86B
Gross profit $15.0M $160.4M $446.3M — $1.04B $1.12B $1.47B $1.85B $2.32B $2.81B
Net income -$141.1M -$142.5M $21.1M $37.0M $407.3M $89.6M $154.5M $249.7M $341.3M $478.6M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Material agreement signed Item 1.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%
TECH BIO-TECHNE Corp $11.38B 62.5x -0.4%